Steroid-converting enzymes in human ovarian carcinomas

Molecular and Cellular Endocrinology

Volumn 301, Issue 1-2, 2009, Pages 51-58

  Chura, Justin C ^a   Ryu, Hyung S ^a   Simard, Marc ^b   Poirier, Donald ^b   Tremblay, Yves ^b   Brooker, Doris C ^a   Blomquist, Charles H ^a   Argenta, Peter A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

17 Hydroxysteroid dehydrogenase; 3 Hydroxysteroid dehydrogenase; 3 Hydroxysteroid dehydrogenase; Estrone sulfatase; Ovarian cancer; Steroid metabolism

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; 3ALPHA HYDROXYSTEROID DEHYDROGENASE; ENZYME INHIBITOR; ESTRADIOL; ESTRONE SULFATE; MESSENGER RNA; TESTOSTERONE; TESTOSTERONE 17BETA DEHYDROGENASE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; METASTASIS; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; SAMPLING;

17-HYDROXYSTEROID DEHYDROGENASES; 3-HYDROXYSTEROID DEHYDROGENASES; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; RNA, MESSENGER; SUBSTRATE SPECIFICITY; SULFATASES; TESTOSTERONE;

EID: 60249091167     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.07.015     Document Type: Article

References (45)

1. Allan G.M., Bubert C., Vicker N., Smith A., Tutill H.J., Purohit A., Reed M.J., and Potter B.V. Novel, potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Mol. Cell Endocrinol. 248 (2006) 204-207
2. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., Copeland L.J., Walker J.L., Burger R.A., and Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
3. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., Sahmoud T., and ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139
4. Beaudoin C., Blomquist C.H., and Tremblay Y. Gene expression of 17beta-hydroxysteroid dehydrogenase type 2 isozyme in primary cultures of human trophoblasts predicts different mechanisms regulating type 1 and type 2 enzymes. Endocrinology 136 (1995) 3807-3814
5. Beaudoin C., Blomquist C.H., Bonenfant M., and Tremblay Y. Expression of the genes for 3 beta-hydroxysteroid dehydrogenase type 1 and cytochrome P450scc during syncytium formation by human placental cytotrophoblast cells in culture and the regulation by progesterone and estradiol. J. Endocrinol. 154 (1997) 379-387
6. Blomquist C.H. Kinetic analysis of enzymic activities: prediction of multiple forms of 17beta-hydroxysteroid dehydrogenase. J. Steroid Biochem. Mol. Biol. 55 (1995) 515-524
7. Blomquist C.H., Bonenfant M., McGinley D.M., Posalaky Z., Lakatua D.J., Tuli-Puri S., Bealka D.G., and Tremblay Y. Androgenic and estrogenic 17β-hydroxysteroid dehydrogenase/17-ketosteroid reductase in human ovarian epithelial tumors: evidence for the types 1, 2 and 5 isoforms. J. Steroid Biochem. Mol. Biol. 81 (2002) 343-351
8. Bydal P., Auger S., and Poirier D. Inhibition of type 2 17β-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships. Steroids 69 (2004) 325-342
9. Bydal, P., Luu-The, V., Poirier, P., in press. Steroidal lactones as inhibitors of 17β-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. Eur. J. Med. Chem.
10. Ciobanu L.C., Luu-The V., Martel C., Labrie F., and Poirier D. Inhibition of estrone-sulfatase induced uterine growth by potent nonestrogenic steroidal inhibitors of steroid sulfatase. Cancer Res. 63 (2003) 6442-6446
11. Day R. Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project. Ann. N.Y. Acad. Sci. 949 (2001) 143-150
12. del Carmen M.G., Fuller A.F., Matulonis U., Horick N.K., Goodman A., Duska L.R., Penson R., Campos S., Roche M., and Seiden M.V. Phase II trial of anastrozole in women with asymptomatic Müllerian cancer. Gynecol. Oncol. 91 (2003) 596-602
13. Deluca D., Krazeisen A., Breitling R., Prehn C., Möller G., and Adamski J. Inhibition of 17beta-hydroxysteroid dehydrogenases by phytoestrogens: comparison with other steroid metabolizing enzymes. J. Steroid Biochem. Mol. Biol. 93 (2005) 285-292
14. Hatch K.D., Beecham J.B., Blessing J.A., and Creasman W.T. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68 (1991) 269-271
15. James V.H.T., Reed M.J., and Folkerd E.J. Studies of estrogen metabolism in postmenopausal women with cancer. J. Seroid Biochem. 15 (1981) 235-246
16. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer statistics CA cancer. J. Clin. 58 (2008) 71-96
17. Jeppsson S., Karisson S., and Kullander S. Gonadal steroids, gonadotropins, and endometrial histology in postmenopausal women with malignant ovarian tumors. Acta Obstet. Gynecol. Scand. 65 (1986) 207-210
18. Judd H.L., Davidson B.J., Frumar A.M., Shamonki I.M., Lagasse L.D., and Ballon S.C. Serum androgens and estrogens in postmenopausal women with and without endometrial cancer. Am. J. Obstet. Gynecol. 136 (1980) 859-871
19. Kaga K., Sasano H., Harada N., Ozaki M., Sato S., and Yajima A. Aromatase in human common epithelial ovarian neoplasms. Am. J. Pathol. 149 (1996) 45-51
20. Kirilovas D., Schedvins K., Naessén T., Von Schoultz B., and Carlström K. Conversion of circulating estrone sulfate to 17β-estradiol by ovarian tumor tissue: a possible mechanism being elevated circulating concentrations of 17β-estradiol in postmenopausal women with ovarian tumors. Gynecol. Endocrinol. 23 (2007) 25-28
21. Labrie F. Intracrinology. Mol. Cell Endocrinol. 78 (1991) C113-C118
22. Labrie F., Belanger A., Simard J., Luu-The V., and Labrie C. DHEA and peripheral androgen and estrogen formation: intracrinology. Ann. N.Y. Acad. Sci. 774 (1995) 16-28
23. Laplante Y., Cadot C., Fournier M.A., and Poirier D. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone. Bioorg. Med. Chem. 16 (2008) 1849-1860
24. Lin H.K., Jez J.M., Schlegel B.P., Peehl D.M., Pachter J.A., and Penning T.M. Expression and characterization of recombinant type 2 3alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17beta-HSD activity and cellular distribution. Mol. Endocrinol. 11 (1997) 1971-1984
25. Moeller G., and Adamski J. Multifunctionality of human 17β-hydroxysteroid dehydrogenases. Mol. Cell Endocrinol. 248 (2006) 43-55
26. NATO writing group. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet 1 (1985) 836-840
27. Penning T.M., Burczynski M.E., Jez J.M., Hung C.F., Lin H.K., Ma H., Moore M., Palackal N., and Ratnam K. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the also-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J. 351 (2000) 67-77
28. Penning T.M. Hydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action. Human Reprod. Update 9 (2003) 193-205
29. Perel E., Wilkins D., and Killinger D.W. The conversion of androstenedione to estrone, estradiol, and testosterone in breast tissue. J. Steroid Biochem. 13 (1980) 89-94
30. Poirier D. Inhibitors of 17β-hydroxysteroid dehydrogenases. Curr. Med. Chem. 10 (2003) 453-477
31. Provost P.R., Blomquist C.H., Godin C., Huang X.F., Flamand N., Luu-The V., Nadeau D., and Tremblay Y. Androgen formation and metabolism in the pulmonary epithelial cell line A549: expression of 17beta-hydroxysteroid dehydrogenase type 5 and 3alpha-hydroxysteroid dehydrogenase type 3. Endocrinology 141 (2000) 2786-2794
32. Provost P.R., Simard M., and Tremblay Y. A link between lung androgen metabolism and the emergence of mature epithelial type II cells. Am. J. Respir. Crit. Care Med. 170 (2004) 296-305
33. Rao G.G., and Miller D.S. Hormonal therapy in epithelial ovarian cancer. Expert. Rev. Anticancer Ther. 6 (2006) 43-47
34. Salehi F., Dunfield L., Phillips K.P., Krewski D., and Vanderhyden B.C. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J. Toxicol. Environ. Health B Crit. Rev. 11 (2008) 301-321
35. Sasano H., Suzuki T., Niikura H., Kaga K., Sato S., Yajima A., Rainey W.E., and Nagura H. 17β-Hydroxysteroid dehydrogenase in common epithelial ovarian tumors. Mod. Pathol. 9 (1996) 386-391
36. Sasano H., Suziki T., and Harada N. From endocrinology to intracrinology. Endocr. Pathol. 9 (1998) 9-20
37. Sasano H., Suzuki T., Nakata T., and Moriya T. New development in intracrinology of breast cancer. Breast Cancer 13 (2006) 129-136
38. Smyth J.F., Gourley C., Walker G., MacKean M.J., Stevenson A., Williams A.R., Nafussi A.A., Rye T., Rye R., Stewart M., McCurdy J., Mano M., Reed N., McMahon T., Vasey P., Gabra H., and Langdon S.P. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin. Cancer Res. 13 (2007) 3617-3622
39. Stanway S.J., Purohit A., Woo L.W., Sufi S., Vigushin D., Ward R., Wilson R.H., Stanczyk F.Z., Dobbs N., Kulinskaya E., Elliott M., Potter B.V., Reed M.J., and Coombes R.C. Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin. Cancer Res. 12 (2006) 1585-1592
40. Steckelbroeck S., Oyesanmi B., Jin Y., Lee S.-H., Kloosterboer H.J., and Penning T.M. Tibolone metabolism in human liver is catalyzed by 3α/3β-hydroxysteroid dehydrogenase activities of the four isoforms of the also-keto reductase (AKR)1C subfamily. J. Pharmacol. Exp. Ther. 316 (2006) 1300-1309
41. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., and Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 18 3 7 (2002) RESEARCH0034
42. Vierikko P., Kauppila A., and Vihko R. Cytosol and nuclear estrogen and progestin receptors and 17 beta-hydroxysteroid dehydrogenase activity in non-diseased tissue and in benign and malignant tumors of the human ovary. Int. J. Cancer 32 (1983) 413-422
43. Walker G., MacLeod K., Williams A.R., Cameron D.A., Smyth J.F., and Langdon S.P. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol. Oncol. 106 (2007) 461-468
44. Watanabe K., Sasano H.N., Ozaki M., Niikura H., Sato S., and Yajima A. Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies. Am. J. Pathol. 146 (1995) 491-500
45. Yamki J., Yamamoto T., and Okada H. Aromatization of androstenedione by normal and neoplastic endometrium in the uterus. J. Steroid Biochem. 22 (1985) 63-66